Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial. - Immunologie-Immunopathologie-Immunothérapie Access content directly
Journal Articles Journal of clinical medicine Year : 2022

Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial.

Raiko Blondonnet
  • Function : Author
Laure-Anne Simand
  • Function : Author
Perine Vidal
  • Function : Author
Lucile Borao
  • Function : Author
Nathalie Bourguignon
  • Function : Author
Dominique Morand
  • Function : Author
Lise Bernard
  • Function : Author
Laurence Roszyk
  • Function : Author
Jules Audard
  • Function : Author
Thomas Godet
  • Function : Author
Marc Garnier
  • Function : Author
Christophe Quesnel
  • Function : Author
Jean-Etienne Bazin
  • Function : Author
Vincent Sapin
  • Function : Author
Julie A. Bastarache
  • Function : Author
Lorraine B. Ware
  • Function : Author
Christopher G. Hughes
  • Function : Author
Pratik P. Pandharipande
  • Function : Author
E. Wesley Ely
  • Function : Author
Emmanuel Futier
  • Function : Author
Bruno Pereira
  • Function : Author
Jean-Michel Constantin
  • Function : Author
Matthieu Jabaudon

Domains

Immunology
Fichier principal
Vignette du fichier
jcm-11-02796-v2.pdf (1.58 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03967648 , version 1 (23-02-2024)

Identifiers

Cite

Raiko Blondonnet, Laure-Anne Simand, Perine Vidal, Lucile Borao, Nathalie Bourguignon, et al.. Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial.. Journal of clinical medicine, 2022, 11, ⟨10.3390/jcm11102796⟩. ⟨hal-03967648⟩
36 View
18 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More